HEPION PHARMACEUTICALS, INC. Additional Paid in Capital
HEPION PHARMACEUTICALS, INC. (HEPA) had Additional Paid in Capital of $247.73 million as of 2026-06-30, per its 10-Q filed 2026-08-13.
Financial Statements › Balance Sheet › Equity › Equity, Attributable to Parent › Additional Paid in Capital
us-gaap:AdditionalPaidInCapital · last filed 2026-08-13
- 2026-06-30: Additional Paid in Capital $247.73M.
- 2026-03-31: Additional Paid in Capital $247.06M.
- 2025-12-31: Additional Paid in Capital $247.06M.
- 2025-09-30: Additional Paid in Capital $247.06M.
| Period end | Additional Paid in Capital |
|---|---|
| 2026-06-30 | $247.73M 10-Q · filed 2026-08-13 |
| 2026-03-31 | $247.06M 10-Q · filed 2026-05-14 |
| 2025-12-31 | $247.06M 10-Q · filed 2026-08-13 |
| 2025-09-30 | $247.06M 10-Q · filed 2025-11-12 |
| 2024-12-31 | $234.25M 10-K · filed 2026-03-12 |
| 2023-12-31 | $230.29M 10-K · filed 2025-04-08 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Transcode Therapeutics, Inc. (RNAZ) | United States | $0.029B | -0.12 |
| KYNTRA BIO, INC. (KYNB) | United States | $0.028B | 0.17 |
| IGC Pharma, Inc. (IGC) | United States | $0.029B | -5.98 |
| BeyondSpring Inc. (BYSI) | United States | $0.031B | -10.95 |
| NANOVIRICIDES, INC. (NNVC) | United States | $0.031B | |
| CHINA PHARMA HOLDINGS, INC. (CPHI) | $0.032B | ||
| AYTU BIOPHARMA, INC (AYTU) | United States | $0.025B | -1.62 |
| Propanc Biopharma, Inc. (PPCB) | $0.032B | -0.13 | |
| NextCure, Inc. (NXTC) | United States | $0.024B | -0.15 |
| TherapeuticsMD, Inc. (TXMD) | United States | $0.024B | -117.87 |